Merovex 500/Merovex 1000 Dosage/Direction for Use

The tables as follows provide general recommendations for dosing.
The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.
A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as nosocomial infections due to Pseudomonas aeruginosa or Acinetobacter spp.
Additional considerations for dosing are needed when treating patients with renal insufficiency (see further follows).
Adults and Adolescents: See Table 1.

Click on icon to see table/diagram/image

Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes.
Paediatric population: Children under 3 months of age: The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen.
Children from 3 months to 11 years of age and up to 50 kg body weight: The recommended dose regimens are shown in the table as follows: See Table 2.

Click on icon to see table/diagram/image

Children over 50 kg body weight: The adult dose should be administered.
Preparation of Solution: For Intravenous Administration: Constitute injection vials (500 mg and 1 g) with sterile Water for Injection. Shake to dissolve and let stand until clear. (See Table 3.)

Click on icon to see table/diagram/image

A solution for bolus injection is prepared by dissolving the drug product in water for injection to a final concentration of 50 mg/ml. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25°C (77°F) or 12 hours under refrigerated conditions 2°C-8°C (36°F-46°F).
A solution for infusion is prepared by dissolving the drug product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20 mg/ml. Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 3 hours at up to 25°C (77°F) or 24 hours under refrigerated conditions 2°C-8°C (36°F-46°F).